Oddo BHF raises target for Novo Nordisk stock to DKK 305

Published on 10/22/2026 at 11:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

CagriSema data showed 25.00 percent weight loss in women on October 20, 2026. Novo Nordisk stock costs EUR 35.05 on October 22, 2026 at Lang & Schwarz.

New obesity data and targets

CagriSema produced 25.00 percent average weight loss in women at 68 weeks on October 20, 2026.
Oddo BHF lifted its target from DKK 221 to DKK 305 on October 20, 2026.
Novo Nordisk stock trades at EUR 35.05 at 11:09 a.m. CEST at Lang & Schwarz on October 22, 2026.

Flatlay mit Spritze, Teststreifen, Notizbuch und Apfel auf weißem Untergrund — Novo Nordisk A/S (DK0062498333): Flatlay mit Spritze, Blutzucker-Teststreifen, Notizbuch und Apfel auf Weiß, Illustration mit AI erstellt.

Novo Nordisk stock is priced at EUR 35.05 at Lang & Schwarz on October 22, 2026 at 11:09 a.m. CEST. The company said on October 20 that its experimental obesity treatment CagriSema produced 25.00 percent average weight loss among women after 68 weeks, according to CNBC.

CagriSema shows a sharper result

The analysis covered 2,309 women with obesity or overweight and compared with 3.00 percent weight loss for placebo. The result came from a post hoc analysis of the phase three REDEFINE 1 study, so it adds a targeted subgroup finding rather than replacing the broader trial result.

In the full study, CagriSema produced 22.70 percent average weight loss at 68 weeks, versus 2.30 percent for placebo, according to Reuters. Novo said the newer analyses were hypothesis-generating and require further study.

What does the target change signal?

Oddo BHF raised its Novo Nordisk target from DKK 221 to DKK 305 on October 20 while retaining a neutral view, as MarketScreener reported. The move puts the target debate alongside the clinical evidence, but the neutral rating keeps the assessment cautious.

Three dated developments

Novo reported adjusted sales of DKK 78.488 billion for the second quarter of 2026 on August 4, with adjusted operating profit of DKK 33.389 billion, according to Novo Nordisk. On October 20, the CagriSema analysis reported 25.00 percent weight loss in women, and Oddo BHF lifted its target to DKK 305.

Next reporting date

Novo Nordisk is scheduled to report third-quarter 2026 results on November 4, 2026, according to MarketBeat. The update will give investors a fresh read on obesity-drug demand, pricing and the development pipeline.

Price and pipeline remain linked

The stock price gives the clinical data immediate market relevance, while the next results offer a separate test of sales execution. Novo Nordisk generated DKK 78.488 billion in adjusted sales in the second quarter of 2026, making the November report the next quantified operating checkpoint.

Novo Nordisk stock was trading at EUR 35.05 at Lang & Schwarz on October 22, 2026 at 11:09 a.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Novo Nordisk stock.